Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMOA1412082/SUPPL_FILE/NEJMOA1412082_DISCLOSURES.PDF.

CAS  Article  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMOA1510665/SUPPL_FILE/NEJMOA1510665_DISCLOSURES.PDF.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMOA1613683.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. https://doi.org/10.1056/NEJMOA1602252.

Article  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMOA1606774.

CAS  Article  PubMed  Google Scholar 

Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.

CAS  Article  PubMed  Google Scholar 

Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563–72. https://doi.org/10.1016/J.JAAD.2021.03.094.

CAS  Article  PubMed  Google Scholar 

Han Y, Wang J, Xu B. Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021. https://doi.org/10.1016/J.CRITREVONC.2021.103376.

Article  PubMed  Google Scholar 

Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73. https://doi.org/10.2147/ITT.S126227.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270(5238):985–8. https://doi.org/10.1126/SCIENCE.270.5238.985.

CAS  Article  PubMed  Google Scholar 

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51. https://doi.org/10.1016/S1074-7613(00)80089-8.

CAS  Article  PubMed  Google Scholar 

Sandigursky S, Mor A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Rheumatol Rep. 2018. https://doi.org/10.1007/S11926-018-0770-0.

Article  PubMed  PubMed Central  Google Scholar 

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7. https://doi.org/10.1016/1074-7613(95)90125-6.

CAS  Article  PubMed  Google Scholar 

Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. https://doi.org/10.1001/JAMADERMATOL.2015.2707.

Article  PubMed  Google Scholar 

Huang SKS, Okamoto T, Morton DL, Hoon DSB. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Investig Dermatol. 1998;111(4):662–7. https://doi.org/10.1046/J.1523-1747.1998.00354.X.

CAS  Article  PubMed  Google Scholar 

Flatz L, Berner F, Bomze D, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1. https://doi.org/10.1001/JAMAONCOL.2019.0402.

Article  PubMed Central  Google Scholar 

Root-Bernstein R, Fairweather DL. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol. 2015;375:101. https://doi.org/10.1016/J.JTBI.2014.11.022.

Article  PubMed  Google Scholar 

Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021;85(4):956–66. https://doi.org/10.1016/J.JAAD.2020.09.054.

CAS  Article  PubMed  Google Scholar 

National Cancer Institute. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0. Published online 2017. https://www.meddra.org/. Accessed 29 Nov 2021.

Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2020;18(3):230–41. https://doi.org/10.6004/JNCCN.2020.0012.

CAS  Article  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01440.

Article  PubMed  Google Scholar 

Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–42. https://doi.org/10.1093/ANNONC/MDX225.

CAS  Article  PubMed  Google Scholar 

Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):2435. https://doi.org/10.1136/JITC-2021-002435.

Article  Google Scholar 

Nadelmann ER, Yeh JE, Chen ST. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol. 2021. https://doi.org/10.1001/JAMAONCOL.2021.4318.

Article  Google Scholar 

Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. https://doi.org/10.1186/S40425-017-0300-Z.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Barrios DM, Phillips GS, Freites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acutedermatologic adverse events impact anticancer therapy interruption: aretrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340. https://doi.org/10.1111/JDV.16159.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol. 2020;82(4):994–6. https://doi.org/10.1016/J.JAAD.2019.09.026.

CAS  Article  PubMed  Google Scholar 

Thompson LL, Li EB, Krasnow NA, et al. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021;185(3):627–35. https://doi.org/10.1111/BJD.20074.

CAS  Article  PubMed  Google Scholar 

Gerstein W, Gniadecki R. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25(1):59–76. https://doi.org/10.1177/1203475420943260.

CAS  Article  PubMed  Google Scholar 

Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2): e001754. https://doi.org/10.1136/JITC-2020-001754.

Article  PubMed  PubMed Central  Google Scholar 

Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15. https://doi.org/10.1038/S41571-020-0352-8.

CAS  Article  PubMed  Google Scholar 

Martins F, Obeid M. Personalized treatment of immune-related adverse events—balance is required. Nat Rev Clin Oncol. 2020;17(8):517. https://doi.org/10.1038/s41571-020-0400-4.

Article  PubMed  Google Scholar 

Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173(1):50–8. https://doi.org/10.1111/BJD.13683.

CAS  Article  PubMed  Google Scholar 

Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020;83(4):1130. https://doi.org/10.1016/J.JAAD.2020.04.105.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68. https://doi.org/10.1200/JCO.2017.77.6385.

CAS  Article  PubMed  Google Scholar 

Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford). 2019;58(Suppl. 7):vii17. https://doi.org/10.1093/RHEUMATOLOGY/KEZ465.